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CHAPTER I
Introduction
I.1 Background
Acute kidney injury (AKI) is a serious condition that his been reported to affect about 2%,
or about 560,000, hospitalizations in the United States annually[7]. Several studies have
shown that the severity of AKI correlates with increase mortality rates and healthcare costs
incurred from prolonged length of stay and post-hospitalization care[3; 7; 10]. While there
are varying degrees for categorizing the severity of AKI[5], the disease is most commonly
characterized by a sudden decrease in kidney function; in effect, the patient’s kidneys lose
their ability to effectively filter out excess waste and fluid from the patient, thus requiring
some cases to use a dialysis machine to help “clean” the patient’s blood.
Furthermore, sepsis has been shown as a common development related with patients
diagnosed with AKI, and its presence correlates with increased mortality among AKI pa-
tients[11]. Fortunately, the prevention and treatment of sepsis is commonly achieved by
the administration of antibiotics, but the dosing of such antibiotics becomes problematic in
the presence of the dialysis procedure; on one hand, drug is being administered to combat
the bacteria involved with the infection; on the other hand, the same drug is being removed
indiscriminately along with the excess waste and fluid by the dialysis machine. Addition-
ally, correct antibiotic dosing is important – too low of a concentration may fail to provide
any benefits, while too high of a concentration may be toxic to the patient. Some an-
tibiotics address this delicate balancing act with certain recommendations that account for
patient variability and dialysis removal, but studies involving patients receiving continuous
renal replacement therapy (CRRT) found that such a broad approach might not produce the
most optimal results. For example, the clinical guidelines for prescribing piperacillin and
tazobactam were still found to be insufficient to account for the wide variability between
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patients, and most of the patients studied were unable to reach the correct antibiotic levels
needed for effective therapy[2]. Similarly, the guidelines for other related antibiotics were
also found to produce insufficient antibiotic concentrations in CRRT patients[12].
To address such difficulties, we first make an observation on how pharmacokinetic mod-
els are usually formed. An experiment is performed where a known amount of drug is ad-
ministered to the patient and the resulting drug concentration in the patient’s blood is then
monitored over time. These observations of the drug concentration are then fit to a curve
that serves as a model describing the underlying pharmacokinetics of the patient. By having
such a model, a physician can then tailor the dosing levels so that the drug concentration in
the patient will be in the therapeutic range.
On the other hand, the presence of dialysis will most likely cause such dosing levels to
be incorrect as both the dosing and the dialysis machine will act on the patient to affect his
drug levels. Note that in this formulation of the problem, the dialysis machine plays the
same role as a drug infusion; both act as external inputs on the patient to affect his drug
levels. Essentially, we are treating the underlying pharmacokinetic structure of the patient
as a constant; only the input to the model changes. Therefore, the “input signal” given by
the dialysis machine, though negative in nature, should have effects on the “output signal”
of the patient’s drug levels in keeping with the underlying pharmacokinetic model of the
patient.
When recast in the terms of an “input signal” acting on a “model” to create an “output
signal”, the dialysis procedure offers a novel opportunity to use the concepts of mathe-
matical systems modeling to asses patient pharmacokinetics. The goal of this thesis is to
explore the use of such concepts by specifically re-framing the dialysis procedure in the
context of linear systems theory; such an analysis will allow for the utilization of some of
the well studied properties offered in that domain. Additionally, the analysis will be able
to inform a procedure that address the problems of wide patient variability and antibiotic
dosing under renal replacement therapy; if the physician is able to quickly and easily create
2
a personalized pharmacokinetic estimate of a particular patient, then the doctor can tailor
the antibiotic dosing specifically for that patient.
I.2 Related Work
Linear systems representations of pharmacokinetic models have been studied in the past,
although not in the context of the dialysis procedure. The work of Cutler [4] gives some
basic results in reframing pharmacokinetics in the language of linear systems theory, while
the work of Anderson [1] and McWilliams and Anderson [9] explore the mathematical
properties of general compartmental pharmacokinetic models in a linear systems context.
In terms of experimental verification, Madden et al. [8] shows good results of applying lin-
ear systems to simulated sets, while the work of [13] shows the applicability on real data.
The method of this thesis bears the most similarity to the CODE algorithm [6] which also
uses a constrained optimization using by using biologically plausible search values. These
aforementioned approaches have shown good results in a traditional pharmacokinetic set-
ting by using data that is collected over a period of four hours. With such results, we hope
to further leverage the utility offered by linear systems theory in the context of dialysis;
due its fast and very noticeable effect of patient drug levels, dialysis offers a novel oppor-
tunity for establishing individualized pharmacokinetics without the need for a dedicated
experiment.
I.3 Overview
This thesis is organized as follows: Chapter 2 serves as a background into basic phar-
macokinetics with the two-compartment model. Chapter 3 re-examines those basic ideas
from a linear systems perspective and focuses on a linear systems representation of the
two-compartment model. Chapter 4 describes a method for utilizing the linear systems
representation of the two compartment model to create pharmacokinetic models from dial-
ysis data. Chapters 5 gives some results on real clinical data while the conclusion is stated
in Chapter 6.
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CHAPTER II
Basic pharmacokinetics and the two-compartment model
One of the most basic mathematical constructs for modeling the pharmacokinetic behavior
of a particular drug is the two-compartment model. While other, more sophisticated models
exist, the two-compartment model is a commonly used, well known model that provides
good insight into the underlying behavior of most drugs. An overview of the model is
shown in Figure II.1.
Figure II.1: Structure of the two-compartment model
The model begins by assuming that the body is essentially two compartments: a central
compartment and a peripheral compartment. For our purposes, we consider that the central
compartment represents the patient’s bloodstream while the peripheral compartment repre-
sents the tissues and other body components not directly related with the patient’s blood.
Let N1(t) and N2(t) represent the amount of drug at time t in the central and peripheral
compartments respectively. If we assume that each compartment is well mixed and that the
volume of each compartment is constant and denoted by V1 and V2, then C1(t) =
N1(t)
V1
and
C2(t) =
N2(t)
V2
are the respective drug concentrations of the central and peripheral compart-
ments at time t.
In addition, assume that drug transport between compartments and with the outside
world is controlled by particular rate constants k12,k21,k10 respectively, and let G(t) repre-
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sent the amount of drug given to the patient at time t. As an added simplification, assume
that the rate of transport between both compartments is equal in both directions, that is,
k12 = k21. From basic diffusion laws involving semi-permeable membranes, we end up
with the following set of coupled differential equations.
N
′
1(t) =−k10c1(t)− k12c1(t)+ k12c2(t)+G(t) (II.1)
N
′
2(t) = k12c1(t)− k12c2(t) (II.2)
As a final simplification to the model, assume that N1(0) = N2(0) = 0, G(t) is admin-
istered as an impulse of magnitude D at time t = 0, and we observe the behavior of the
system only after the infusion ends. Furthermore, since we are more concerned with the
concentration of drug in the patient rather than the absolute amount of drug, we divide both
equations by their respective volumes. Equations II.1 and II.2 then simplify to:
dc1(t)
dt
=−k10+ k12
V1
c1(t)+
k12
V1
c2(t) (II.3)
dc2(t)
dt
=
k12
V2
c1(t)− k12V2 c2(t) (II.4)
Since the bolus drug infusion of magnitude D must either have been eliminated or still in
the tissues, we can write the following equation based on mass balance
D = c1(t)V1+ c2(t)V2+
∫ t
0
k10c1(t)dt
Or, rearranging:
c2(t) =
D− c1(t)V1−
∫ t
0 k10c1(t)dt
V2
(II.5)
We then substitute equation II.5 into equation II.3 to get an expression for the rate of
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change of drug concentration in the patient’s blood
dc1(t)
dt
=−k10+ k12
V1
c1(t)+
k12
V1
(
D− c1(t)V1−
∫ t
0 k10c1(t)dt
V2
)
Removing the integral from the above expression involves taking the derivative with respect
to t:
d2c1(t)
dt2
=−k10+ k12
V1
dc1(t)
dt
+
k12
V1
(
−dc1(t)dt V1− k10c1(t)
V2
) (II.6)
The above now represents a second order differential equation for c1(t). The solution to
that equation is of the form:
c1(t) = Ae−αt +Be−β t (II.7)
Where A, B, α , and β are constants. Furthermore, equation II.7 represents the concentration
of drug in the patient’s bloodstream at time t. Therefore, the traditional approach to creating
a pharmacokinetic model is to inject a bolus into a patient and then collect many samples
of the drug concentration in the patient’s blood. The collected data can then be used to
fit a sum of exponentials curve of the form given in equation II.7. Finally, the resulting
constants A, B, α , and β are then used to estimate the original parameters as follows:
k10 =
Dαβ
Aβ +Bα
k12 =
D(Aα+Bβ )
(A+B)2
− Dαβ
Aβ +Bα
V1 =
D
A+B
V2 =
(Aα+Bβ )
(A+B)(Aβ +Bα)
− αβ (A+B)
(Aβ +Bα)2
While the above analysis has been shown to be effective in producing pharmacokinetic
models for patients, there are two aspects of the model that we would like to revisit:
1. Curve fitting an exponential model to the collected data
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2. Assuming an idealized bolus infusion as the input
In effect, the above discussion relies on using least squares curve fitting approaches on col-
lected data; such techniques may require many samples in order to overcome such methods’
sensitivity to noise and outliers. The obvious flaw in this requirement is the fact that, in or-
der to minimize patient risk, only a limited amount of blood can be sampled in a given time
frame. Furthermore, the need to fit an exponential curve to the data was motivated by the
assumption that there was an idealized bolus infusion as the input to the two-compartment
model. Therefore, to perform the preceding analysis in a clinical setting, one has to set
up a dedicated experiment in which a bolus is injected and the patient is monitored for a
long period of time so that enough data can be collected to perform a least squares fit of a
pharmacokinetic model.
The dialysis procedure, on the other hand, offers a potential solution to both of the
above drawbacks. First, for the patients that we wish to create pharmacokinetic models
for, dialysis is a necessary procedure that must be performed anyway; there is no need to
create a separate lengthy experiment for assessing the patient’s pharmacokinetics. Further-
more, since the machine can be precisely controlled and the removed drug concentration
in the dialysate can be monitored, we needn’t constrain ourselves to assuming bolus drug
infusions; rather, we can observe the dialysis procedure as administering a “negative” drug
dose whose exact value over time can be precisely measured. That “negative input sig-
nal” along with the “output signal” measured from the patient’s blood suggests that we can
take a linear systems approach in creating an individualized pharmacokinetic model for a
particular patient.
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CHAPTER III
A linear systems approach to pharmacokinetics
III.1 A general linear model
We base our initial analysis of the dialysis procedure on the traditional difference equa-
tion for linear systems. Let y[0],y[1], . . . ,y[n− 1] be the n equally spaced samples of the
drug concentration in the patient’s blood. In addition, let x[0],x[1], . . . ,x[n−1] be the cor-
responding drug concentration samples in the dialysate. If we assume that the ith blood
sample has a concentration y[i] that is a linear combination of the current dialysate sample
x[i], the previous q dialysate samples x[i−1],x[i−2], . . . ,x[i−q], and the previous p blood
samples y[i−1],y[i−2], . . . ,y[i− p], then the difference equation can be written as:
y[i] =−a1y[i−1]−a2y[i−2]− . . .−apy[i− p]+b0x[i]+b1x[i−1]+ . . .+bqx[i−q] (III.1)
Where a1, . . . ,ap,b0, . . . ,bq are unknown filter coefficients. Taking the Z-transform of both
sides yields:
Y (z) =−Y (z)(a1z−1+a2z−2+ . . .+apz−p)+X(z)(b0+b1z−1+b2z−2+ . . .+bqz−q)
Rearranging terms gives an expression for the transfer function of the linear system H(z)
H(z) =
Y (z)
X(z)
=
b0+b1z−1+b2z−2+ . . .+bqz−q
1+a1z−1+a2z−2+ . . .+apz−p
(III.2)
Such an expression means that, once the values of the unknown coefficients, a1, . . . ,ap,
b0, . . . ,bq, are determined, an output response can be predicted from any arbitrary input
signal. Note that the form in equation III.2 can be tailored by a user’s choice for the values
of p and q; one can make higher or lower order models as needed, given enough data exist
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to support the chosen model.
In order to determine the values for the unknown coefficients of equation (III.2), we
return to the original difference equation given by equation (III.1). We start by writing
a difference equation for each of the n−M output samples, where M = max(p,q). Let
~y = [ y[M] y[M+1] ... y[n−1] ]>. Furthermore, let ~a = [a1 a2 ... ap ]> and~b = [b0 b1 ... bq ]> be the
vectors of unknown coefficients for the model from equation III.1. The resulting matrix
equation can then be set up:
~y =
[
Y X
]~a
~b
 (III.3)
Where Y and X are the Toeplitz matricies consisting of the respective output and input
samples as follows:
Y=

y[M−1] y[M−2] . . . y[M− p]
y[M] y[M−1] . . . y[M+1− p]
y[M+1] y[M] . . . y[M+2− p]
...
...
...
...
y[n−2] y[n−3] . . . y[n− p−1]

X=

x[M] x[M−1] . . . x[M−q]
x[M+1] x[M] . . . x[M+1−q]
x[M+2] x[M+1] . . . x[M+2−q]
...
...
...
...
x[n−1] x[n−2] . . . x[n−q−1]

Equation (III.3) can then be solved by any variety of techniques, usually involving least-
squares. Again, we stress the generality of the aforementioned approach; the output re-
sponse of a patient can be predicted from any arbitrary input signal without any particular
assumption of the underlying pharmacokinetic model of the patient.
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Figure III.1 shows the validity of such an approach. A patient was simulated in MAT-
LAB by using the original coupled differential equations of the two-compartment model.
Simulated doses were given as square pulses until the patient reached steady state. A
simulated dialysis session was then applied to the patient for fifteen minutes. We took a
sample of the drug concentration of the blood and the dialysate at each minute during the
15 minute dialysis session and in the 285 minute period immediately after the dialysis ses-
sion had completed(For a total of 300 samples). Using p = q = 10 the values for the filter
coefficients were found with the least-squares approach stated above. We then used the re-
sulting estimated model to filter the original sequence of simulated doses to get the results
in Figures III.1d and III.1e. Note that we were able to create a close approximation of the
original model’s steady state behavior without any knowledge of the underlying system;
the choice of p = q = 10 was completely arbitrary and could be changed to any value that
would be supported by having 300 sample pairs.
While such a simulation shows that one has the potential to create arbitrarily good
approximations without any particular concern for the underlying pharmacokinetics, the
utility of the general least squares approach is still hindered by the need of many samples
in order to create higher order models and to overcome sensitivities to outliers and noise.
Such limitations necessarily arise from the very general nature of this approach to system
modeling, as we are essentially searching for the best model (in a least-squares sense)
among all possible models. This large of a search space is unnecessary; since we are
modelling patients instead of arbitrary black boxes, we can constrain the search space by
searching only for models that are plausible in a biological sense. In doing so, we can
minimize the number of samples required to still create models that can predict the output
response for any arbitrary input.
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(a) Simulated Data
(b) Drug concentration in dialysate (c) Drug concentration in blood
(d) Output of predicted model (e) Steady state behavior of the predicted model
Figure III.1: Simulated example illustrating the least-squares approach
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III.2 A linear systems analysis of the two-compartment model
To understand what transfer functions are acceptable in a biological sense, we return to the
two-compartment model and observe how the biological parameters V1,V2,k10,k12 behave
in a linear systems context.
Recall that the core of the two compartment model was the following set of coupled
differential equations.
c′1(t) =−
k10+ k12
V1
c1(t)+
k12
V1
c2(t)+
1
V1
G(t)
c′2(t) =
k12
V2
c1(t)− k12V2 c2(t)
Taking the Laplace transform of both equations yields:
C1(s) · s =−k10+ k12V1 C1(s)+
k12
V1
C2(s)+
1
V1
G(s)
C2(s) · s = k12V2 C1(s)−
k12
V1
C2(s)
Or, in matrix form:
C1(s)
C2(s)
s =
−k10+k12V1 k12V1
k12
V2
−k12V1

C1(s)
C2(s)
+
 1V1
0
G(s)
Rearranging, we get:
(sI−
−k10+k12V1 k12V1
k12
V2
−k12V1
)
C1(s)
C2(s)
=
 1V1
0
G(s)
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Where I is the identity matrix. The solution to this system is therefore:
C1(s)
C2(s)
= (sI−
−k10+k12V1 k12V1
k12
V2
−k12V1
)−1
 1V1
0
G(s)
Since the blood samples taken from the patient reflect our observations of C1, we are
most interested in the transfer function H(s) = C1(s)G(s) as that succinctly characterizes the
relationship between a drug dose and the drug concentration in the blood. Multiplying both
sides by [1 0 ] and rearranging terms creates a transfer function of the form:
H(s) =
C1(s)
G(s)
=
1
V1
s+ 1k10 BH
s2+AHs+BH
(III.4)
Where:
AH =
k12
V2
+
k10+ k12
V1
BH =
k10k12
V1V2
Note that the form in equation (III.4) is the continuous s-domain transfer function rela-
tionship between the blood’s drug concentration and dosing input. In reality, since we are
observing the blood concentrations through discrete samples, the transfer function must be
converted to its discrete time z-domain representation. If the time between samples is T ,
we perform the conversion with the bilinear transform by evaluating H(s) at s = 2T · 1−z
−1
1+z−1 .
The resulting expression gives a discrete time transfer function of the form:
H(z) = H(s)
∣∣∣∣ 2
T · 1−z
−1
1+z−1
=
b0+b1z−1+b2z−2
1−a1z−1−a2z−2 (III.5)
Where the coefficients of the transfer function are:
b0 =
2T
V1
+ 1k10 T
2BH
4+2TAH +T 2BH
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b1 =
2
k10
T 2BH
4+2TAH +T 2BH
b2 =
1
k10
T 2BH− 2TV1
4+2TAH +T 2BH
a1 =
2T 2BH−8
4+2TAH +T 2BH
a2 =
4−2TAH +T 2BH
4+2TAH +T 2BH
III.3 Properties of the two-compartment model with biological parameters
Notice that the preceding discussion shows that the original coupled differential equations
that describe the traditional two-compartment model can be transformed into transfer func-
tions in either the continuous or discrete domain. Furthermore, we notice that the co-
efficients of the filters are constants that are dependent on the constants of the original
two compartment parameters. Here we describe some interesting properties of the two-
compartment model when using biologically plausible values for V1,V2,k10,k12
Property 1. V2 ≥V1 is a sufficient condition for the poles of H(z) to be real
Proof. For this fact, we simply need to observe the value of the determinant of the denom-
inator of H(z). Simplifying that expression (in Mathematica) yields:
a21+4a2 = 16
T 2(k210V
2
2 +2k10k12V2(V2−V1)+ k212(V1+V2)2)
(k12T (k10T +2V1)+2((k10+ k12)T +2V1)V2)2
(III.6)
Because the values for V1,V2,k10,k12 are greater than zero, a only the middle term in the
numerator (V2−V1) could lead to a negative value. Therefore, a sufficient condition for
real poles is that V2 ≥ V1. This condition V2 ≥ V1 is reasonable to expect, as V1 represents
the volume of the blood while V2 represents everything else.
Property 2. The two compartment model is stable when using biological values
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Proof. This is most easily seen by using the continuous representation of the transfer func-
tion H(s), restated here for convenience:
H(s) =
1
V1
s+ k12V1V2
s2+(k12V2 +
k10+k12
V1
)s+ k10k12V1V2
Since the denominator of H(s) is second order, we can use a special case of the Routh-
Hurwitz stability criterion which simply requires the coefficients of the denominator to
have the same sign. Indeed, this is the case as biologically plausible values of V1,V2,k10,k12
must necessarily be greater than zero and will thus cause the coefficients of the denominator
to all be positive.
Property 3. One of the zeros of H(z) is equal to −1
Proof. In the interest of clarity, we exclude the denominators of b0,b1, and b2 as they are
equivalent and will not affect our analysis in finding the zeros of the numerator of H(z).
First observe the value of the discriminant b21−4b0b2
b21−4b0b2 = (
2
k10
T 2BH)2−4( 1k10 T
2BH +
2T
V1
)(
1
k10
T 2BH− 2TV1 )
=
4
k210
T 4B2H−
4
k210
T 4B2H +16
T 2
V 21
= 16
T 2
V 21
Since this result must necessarily be positive, an interesting side note is that the zeros of
H(z) will in fact be real. Now observe one of the roots of the numerator of H(z)
−b1−
√
b21−4b0b2
2b0
=
− 2k10 T 2BH−
√
16T
2
V 21
2( 1k10 T
2BH + 2TV1 )
=
−1( 2k10 T 2BH +
4T
V1
)
2
k10
T 2BH + 4TV1
= −1
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Property 4. The numerator of H(z) can be rewritten as b0+(b0+b2)z−1+b2z−2
Proof. Again, we ignore the denominators of b0,b1, and b2 as they are equivalent
b0+b2 = (
1
k10
T 2BH +
2T
V1
)+(
1
k10
T 2BH− 2TV1 )
=
2
k10
T 2BH
= b1
The above properties allow for some interesting observations on the behavior of the
two compartment model we will be searching for. From properties 1 and 2 we know that
the impulse response from an idealized bolus infusion will be expected to be stable and
behave as a sum of decaying exponentials. Furthermore, property 3 implies that the model
has an inherent low-pass characteristic. These behaviors are expected, as these properties
are identical to the behaviors observed from our original analysis of the two-compartment
model. However, with this analysis in creating transfer functions H(s) and H(z), we can
describe the response of the model to any input signal, rather than limiting ourselves to
considering just idealized bolus infusions.
Property 4 is particularly interesting as we can now rewrite the form of H(z) from
equation III.5 as follows:
H(z) =
b0+(b0+b2)z−1+b2z−2
1−a1z−1−a2z−2 (III.7)
This form of a model from equation III.7 means that a vector of biologically feasible values
for V1,V2,k10,k12 will map to a vector of model coefficients a1,a2,b0,b2, thus implying a
search for 4 coefficients instead of the original 5. Along with the other properties stated,
we see that such a search using biologically reasonable parameters for a two-compartment
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model further constrains the search space of all possible linear models to a space of stable
linear models that have two real poles and two real zeros with one zero fixed at -1.
17
CHAPTER IV
Methods
IV.1 Data Collection
In order to use the information found in the preceeding section about biologically plausible
two-compartment models, we first note the typical response of a two-compartment model
when dialysis is applied. Figure IV.1 shows the output response of a two-compartment
model in both simulations and in a preliminary pilot study. Figure IV.1a is the same graph
from the simulated two-compartment model used in the preceeding section. Meanwhile,
Figure IV.1b shows the drug level of a pharmacokinetic experiment involving a patient
under continuous renal replacement therapy (CRRT). For the simulated example, we see
(a) Simulated two-comparment patient (b) Real CRRT Patient
Figure IV.1: Response of patient drug levels from turning off the dialysis machine
the drug levels in the blood increase slightly when dialysis ends; this movement is rep-
resentative of the transfer of drug from the peripheral compartment back into the central
compartment. A similar effect can be seen in the real CRRT case as the green circles indi-
cate when the dialysis machine was turned off in order to perform a bag change. Note both
examples illustrate the presence of characteristic changes in drug concentration not only
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when the dialysis machine is on, but also when it is turned off. As these transient responses
are highly informative of the behavior of the underlying pharmacokinetic system, we will
use the following collection strategy:
1. Turn the dialysis machine on
2. Collect N2 pairs of blood and dialysate by sampling every T minutes
3. Turn the dialysis machine off and place the patient under ultrafiltration.
4. Immediately begin the collection of the other N2 samples of blood and dialysate pairs
by sampling every T minutes
This strategy will then give us N evenly spaced samples of the input x[0],x[1], . . . ,x[N2 −
1],x[N2 ],x[
N
2 +1], . . . ,x[N−1] and output y[0],y[1], . . . ,y[N2 −1],y[N2 ],y[N2 +1], . . . ,y[N−1]
signals of the dialysate and blood respectively.
IV.2 Model Estimation
We then set up the same matrix equation as equation III.3. Since we will be looking for
a two-compartment model with two poles and two zeros, we form equation III.3 with p =
q = 2. Let~y = [ y[2] y[3] ... y[N−1] ]> and ~θ = [a1 a2 b0 b1 b2 ]>. Equation III.3 now becomes:
~y = A~θ (IV.1)
Where A is the matrix:
A=

y[1] y[0] x[2] x[1] x[0]
y[2] y[1] x[3] x[2] x[1]
y[3] y[2] x[4] x[3] x[2]
...
...
...
...
...
y[N−2] y[N−3] x[N−1] x[N−2] x[N−3]

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This time, however, we will not be solving for the unknown coefficients in the vector
~θ directly. Since the number of samples N will most likely be too small for an accurate
estimation by a direct application of least-squares, we will use our knowledge of biological
parameters to set up a search space involving V1,V2,k10,k12 with the following constraints:
1. V1,V2,k10,k12 are all greater than V1Min,V2Min,k10Min,k12Min respectively.
2. V1,V2,k10,k12 are all less than V1Max ,V2Max ,k10Max ,k12Max respectively.
These max and min values can be chosen by the physician and needn’t be strict; these are
simply to limit the search space to models that have a plausible interpretation. Furthermore,
since we know that any choice of V1,V2,k10,k12 in this search space can be mapped to a
point in the space of filter coefficients a1,a2,b0,b2, a search in our constrained search
space corresponds to a search in the coefficient space. Therefore, we try to optimize the
parameters V1,V2,k10,k12 by minimizing the squared error in equation IV.1. More formally:
minimize
~x
(~y−A f (~x))2
subject to [V1Min V2Min k10Min k12Min ]> ≤~x≤ [V1Max V2Max k10Max k12Max ]>
(IV.2)
Where ~x = [V1 V2 k10 k12 ] and f (~x) is the function that maps ~x to the vector of filter coeffi-
cients ~θ , using the formulas from the previous section. As the minimization objective in
equation IV.2 is difficult to evaluate in closed form, we adopt a random search procedure
to identify potential candidate models. A set of K candidate vectors of biological param-
eters ~xi within our constrained search space are randomly generated. The minimization of
equation IV.2 for each of the K candidates is then performed using the Nelder-Mead op-
timization algorithm. We note that in performing this optimization, the input and output
values x[n] and y[n] should be scaled so that the range of the input values should be roughly
on par with the range of the output values; we noticed that if the x[n] values are too large
with respect to the y[n] values, the Nelder-Mead optimization would tend to push candidate
models to the fringe of the biological search space rather than pushing each of the models
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toward a local minima. Furthermore, as Nelder-Mead is an iterative approximation method,
there is the potential that certain candidates may have gotten stuck in local minima that are
not very meaningful. Therefore, we choose the B best candidate models based on their final
squared error values.
However, recall that the behavior of a transfer function H(z) is dictated by the value
of its poles and zeros rather than the actual value of its coefficients; two transfer functions
may behave similarly from having similar poles and zeros but have completely different
values in terms of filter coefficients. To account for this fact, we take each of the transfer
functions represented by each of the B best candidate models and re-parametrize them by
their poles and zeros. Our final estimated model is simply the average of the B best models
in pole-zero space. If the ith model is represented by the vector ~mi = [p1i, p2i,z1i,−1]>
where p1i and p2i are the poles of the ith model and z1i is the zero that does not equal -1,
then our model estimate ~ˆM is therefore:
~ˆM =
1
B
B
∑
i=1
~mi (IV.3)
The poles and zeros represented by ~ˆM can be used to estimate a filter Hˆ(z). However,
a filter constructed only from the poles and zeros will produce a filter with only unity gain.
Therefore, as a final step, we still need to find a gain value Gˆ to fully estimate the behavior
of our filter. To accomplish this goal, we use the patient’s medical history leading up to
dialysis as follows:
1. Simulate an input signal X(t) of the patient’s dosing history as a sequence of square
pulses
2. Filter X(t) with Hˆ(z) to produce Yˆ (t)
3. If the first blood sample at the start of dialysis was taken at t f irstsample, Gˆ should be
calculated as the value that scales Yˆ (t f irstsample) to the actual value measured at the
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start of dialysis.
In other words, we treat the first blood sample taken at the start of dialysis as the “correct”
drug concentration that resulted from the previous doses and calculate the gain of the es-
timated filter to reflect that fact. Now that an estimate of Gˆ and Hˆ(z) have been found,
a physician can easily predict the patient’s drug levels in response to any arbitrary dosing
scheme.
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CHAPTER V
Results and Discussion
V.1 Experimental Setup
Four data sets were collected on three patients receiving dialysis. More specific information
on the patients and data is described in the next subsection. Each dataset was broken
into two parts, dialysis day data and non-dialysis day data. The dialysis day data was
collected in the same manner described in the previous section; we collected six samples
at 5 minute intervals during the start of dialysis, and then collected six more samples at 5
minute intervals as soon as the dialysis machine was turned off. This data was then used
to search for a filter based on the two compartment model; V1Max and V2Max were set to the
patient’s weight, while k10Max , and k12Max were set to 1000. Also,V1Min and V2Min were set
at 1000, while k10Min, and k12Min were set to 1. The number of candidate models we used
in our search was 1000. We then simulate the patient’s dosing history leading up to the
times of the samples collected on his non-dialysis day. This simulated signal is then fed
through our estimated filter to get predictions for the patient’s drug concentration during
his off-dialysis day. These predictions are compared to the actual measured values to assess
method accuracy.
V.2 Individual Patient Results
Patient 1
This was a 97kg patient dosed with two antibiotics: piperacillin and tazobactam. This
combination allowed us to get two datasets, one each for the piperacillin concentrations
and the tazobactam concentrations. Both drugs were administered to the patient every
12 hours with infusions of 3.375g spread out over four hours. The non-dialysis data was
collected 3 days after the start of infusions and the dialysis day data was collected later
on the same day. Dialysis flow rate was 800ml/min while the ultrafiltration rate was set to
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14.5ml/min. From the final squared errors of the candidate models, we chose to average
the smallest 700 models.
Predicted 25.49 24.50 23.51 21.71 18.56
Measured 23.10 22.88 21.55 20.87 19.18
%Error 10.33 7.08 9.08 4.02 3.21
Table V.1: Comparison of predicted and measured values for non-dialysis day in the
tazobactam dataset for patient 1
Predicted 188.59 181.75 174.93 162.46 140.46
Measured 194.31 191.55 181.04 173.43 152.30
%Error 2.93 5.12 3.38 6.32 7.77
Table V.2: Comparison of predicted and measured values for non-dialysis day in the
piperacillin dataset for patient 1
Patient 2
This was a 100kg patient injected with meropenem. Drug was administered every 8 hours
with infusions of 1 gram spread out over three hours. The non-dialysis day data was col-
lected 5 days after the start of infusions while the dialysis day data was collected the follow-
ing day. Dialysis flow rate was set to 800ml/min while ultrafiltration was set to 4.16ml/min.
From the final squared errors of the candidate models, we chose to average the smallest 800
models.
In looking at the collected dialysis day data, the circled point in Figure V.3a appears to
be an erroneous measurement and its inclusion does lead to a poor model estimation.(Figure
V.3) However, when that data point is excluded, (along with the next two points since
they depend on the excluded point) the estimation method appears to produce reasonable
results.(Figure V.4)
Patient 3
This was a 102kg patient dosed with piperacillin. Drug was administered every 12 hours
with infusions of 3.375g spread out over four hours. Dialysis day data was collected the
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(a) Observed data from dialysis
(b) Final errors of candidate models (c) Simulated dosing history of patient
(d) Predicted drug levels (e) Comparison with ground truth
Figure V.1: Results on piperacillin dataset for patient 1
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(a) Observed data from dialysis
(b) Final errors of candidate models (c) Simulated dosing history of patient
(d) Predicted drug levels (e) Comparison with ground truth
Figure V.2: Results on tazobactam dataset for patient 1
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(a) Observed data from dialysis
(b) Final errors of candidate models (c) Simulated dosing history of patient
(d) Predicted drug levels (e) Comparison with ground truth
Figure V.3: Results on meropenem dataset for patient 2
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(a) Observed data from dialysis excluding the
outlier
(b) Final errors of candidate models
(c) Predicted drug levels (d) Comparison with ground truth
Figure V.4: Results on meropenem dataset for patient 2 when excluding the outlier
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Predicted 43.82 31.98 23.33 12.42 3.52
Measured 58.39 59.03 59.90 57.21 46.86
%Error 25.94 45.82 61.04 78.28 92.48
Table V.3: Comparison of predicted and measured values for non-dialysis day in the
meropenem dataset for patient 2 using all of the data
Predicted 64.58 60.45 56.58 49.57 38.05
Measured 58.39 59.03 59.90 57.21 46.86
%Error 10.60 2.39 5.54 13.35 18.80
Table V.4: Comparison of predicted and measured values for non-dialysis day in the
piperacillin dataset for patient 2 excluding the suspected outlier
day following the start of infusions. We note here that there was some ambiguity in the
medical record as to the nature of the last dose given to the patient before the dialysis data
was taken. According to the chart, the dose should have ended during the collection of the
dialysis data. However, according to the nurse, there was no observable amount of drug
left in the I.V. bag. This leads to an ambiguity as to exactly the rate and the amount of drug
was given to the patient during the last dose, and if the infusion of drug was interfering
with the drug removal from the dialysis machine. Nonetheless, we model the final dose
as if the infusion ended when it was scheduled (during dialysis) and then calculating the
overlapping values by subtracting the amount of drug present in the measured dialysate
samples. The dialysis flow rate was set to 800ml/min while the ultrafiltration rate was
set to 4.1667ml/min. From the final squared errors of the candidate models, we chose to
average the lowest 900 models.
After the data was collected for the dialysis day samples, the patient received a 4 hour
dialysis session. The patient then did not receive another dose for another 24 hours later.
From these two facts, we assume that the patient had reached a drug concentration of zero.
Therefore, we model the next set of doses leading up to the collection of the non-dialysis
day data to reflect this assumption. These doses were also modeled as 12 hour infusions
of 3.375g spread out over four hours. The non dialysis day data was collected the day
following the start of this new set of infusions.
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(a) Observed data from dialysis (b) Simulated dosing history leading to dialysis
day
(c) Final errors of candidate models (d) Simulated dosing history leading to off-day
data
(e) Predicted drug levels (f) Comparison with ground truth
Figure V.5: Results on piperacillin dataset for patient 3
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Predicted 217.55 213.66 209.83 202.39 188.28
Measured 244.53 246.62 251.00 244.38 203.22
%Error 11.03 13.36 16.40 17.18 7.35
Table V.5: Comparison of predicted and measured values for non-dialysis day in the
piperacillin dataset for patient 3
V.3 Discussion
Our results on the real clinical data suggest that our method of pharmacokinetic modeling
has some potential. For patient 1, our method had its best performance by successfully
predicting both drugs to less than 10% average error. Our method had less success for the
other two patients, but still produced reasonable predictions of less than 20% average error.
We further note that our models created predictions for drug levels that occurred days after
the start of a dosing regimen; the predictions for patient 1 were three days in the future
while the future predictions of patients 2 and 3 were five days and two days respectively.
Additionally, we note an interesting observation of final squared errors of our candidate
models; for all of the datasets, a significant portion of the randomly generated models, when
optimized using Nelder-Mead, converged to the exact same set of biological parameters.
Such a result suggests that the error surface of biological parameters is not very “hilly”.
Furthermore, since so many of the points ended up in the same place, one could achieve
faster performance by reducing the number of candidates to optimize. Nonetheless, our
method was still reasonable in terms of computing resources; when searching with 1000
possible models, a MacBook Pro laptop was able to perform the computation in under five
minutes.
In terms of the limitations of our approach, we have already noted some of the problems
with the datasets of patients 2 and 3; patient 2 had a questionable data point while patient
3 had some ambiguity in the reporting of his dosing schedule. Thus, in the presence of
truly “strange” data, we cannot expect very good predictions on the order of patient 1.
However, it should also be noted that the off-day dialysis data for any of the datasets do
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not follow a smooth trend in keeping with the expected behavior of a two-compartment
model; measurement noise could be an obvious factor in this observation, but there also
exists the possibility that there are unmodeled factors in the biology of the patient that
cause deviations from a two-compartment pharmacokinetic behavior. Nevertheless, the
quality of our predictions suggest the robustness of our approach and the strength of the
two compartment model as an underlying assumption.
In moving forward, more datasets need to first be collected in order to better identify and
describe this method’s strengths and weaknesses. In particular, the question of the method’s
robustness across the wide variation in patients and drugs still need to be addressed. Fur-
thermore, when answering that question, traditional pharmacokinetic experiments should
be performed; due to the limited scope of our study, we were only able to collect samples
for validation during a small 4 hour window corresponding to the non-dialysis day; it is
difficult to know exactly what the patient’s actual drug levels looked like outside of that
window. Additionally, looking at drug and patient variability can lead to more informed
choices in setting up the constraints for the model search space. Finally, a more rigorous
understanding of the mapping between biological parameters and filter coefficients should
take place; while our estimates of Hˆ(z) and Gˆ can be mapped back to a set of biological
parameters, we are unsure if those are the correct set of biological parameters; the cor-
rect model that may be “close by” our estimate in the space of filter coefficients does not
necessarily imply that it is “close by” our biological parameter estimate and vice versa.
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CHAPTER VI
Conclusion
Correct antibiotic dosing is important in the prevention and treatment of sepsis for patients
with AKI. While dialysis is also necessary in the treatment of AKI, its presence compli-
cates effective dosing using strategies derived from lengthy “one-size-fits-all” phamacoki-
netic experiments. However, by interpreting the dialysis procedure as a “negative input
signal” to a linear system, the methods of linear systems theory can provide insight into an
individual’s pharmacokinetics. While collecting lots of data can provide arbitrarily good
approximations to this underlying model, we have shown that a few samples collected dur-
ing the first hour of dialysis can be used with a linear systems representation of the two
compartment model to potentially produce reasonable predictions of drug levels days in the
future. The presence of such a procedure can enable physicians to no longer view dialysis
as a hinderance to antibiotic dosing; rather, the data collected during dialysis can be seen as
a helpful tool in tailoring antibiotic dosing schemes that are specific to individual patients.
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